Summary

118.57 -0.23(-0.19%)11/18/2025
Zoetis Inc. (ZTS)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 Years
-0.19-1.10-17.25-21.73-27.04-31.76-23.98


Last 730 data points are shown. To view all data, Upgrade to PRO plan!


Fundamental Ratings
CategoryRating
Main RatingA-
Recommended RatingBuy
DCFBuy
ROEStrong Buy
ROAStrong Buy
Debt/EquityNeutral
P/ESell
P/BStrong Sell


Earnings
  • ZTS reported last earnings on 2025-11-04 after the market.
  • An EPS of $1.7 was observed compared to an estimated EPS of $1.62, resulting in a surprise value of $0.08.
  • A revenue of $2,400 million was observed compared to an estimated revenue of $2,410 million, resulting in a surprise value of $-10 Million.


  • Trading Data
    Close118.57
    Open118.43
    High119.13
    Low117.09
    Volume5,180,617
    Change-0.23
    Change %-0.19
    Avg Volume (20 Days)4,309,215
    Volume/Avg Volume (20 Days) Ratio1.20
    52 Week Range119.56 - 179.46
    Price vs 52 Week High-33.93%
    Price vs 52 Week Low-0.83%
    Range0.00
    Gap Up/Down-1.19
    Profitibility
    Market Capitalization (Mln)52,738
    Revenue per share21.2170
    Net Income per share5.9855
    Dividend Yield0.0169
    Dividend Share200.00%
    Valuations
    Enterprise Value0.00%
    PE Ratio19.7375
    PB Ratio0.0000
    PTB Ratio0.0000
    Liquidity
    Debt/Equity Ratio0.0000
    Net Debt/EBIDTA Ratio0.0000
    Current Ratio0.0000
    Enterprise Value and Cash Flow
    EV/Sales Ratio0.0000
    EV/EBIDTA Ratio0.0000
    EV/Free Cash Flow Ratio0.0000


    11/15 10:00 EST - fool.com
    2 Outstanding Dividend Stocks That Are Too Cheap to Ignore
    Both stocks trade at once-in-a-decade low valuations and have all-time high dividend yields. Each company leads in its niche, but both are battling through minor challenges.
    11/15 03:44 EST - defenseworld.net
    Analyzing Zoetis (NYSE:ZTS) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
    Zoetis (NYSE: ZTS - Get Free Report) and Shionogi and Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk,...
    11/14 11:35 EST - forbes.com
    Zoetis: A High-Quality Compounder Now On Sale?
    Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months as softer clinic traffic, uneven companion-animal demand, and a narrowed full-year outlook weighed...
    11/14 08:03 EST - 247wallst.com
    Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up
    The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.
    11/14 04:36 EST - defenseworld.net
    Allianz SE Raises Holdings in Zoetis Inc. $ZTS
    Allianz SE increased its stake in shares of Zoetis Inc. (NYSE: ZTS) by 30.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,923 shares of the company's stock after acquiring an additional 684...
    11/13 12:41 EST - zacks.com
    CPRX vs. ZTS: Which Stock Is the Better Value Option?
    Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
    11/12 04:30 EST - defenseworld.net
    Allworth Financial LP Buys 3,789 Shares of Zoetis Inc. $ZTS
    Allworth Financial LP increased its stake in shares of Zoetis Inc. (NYSE: ZTS) by 8.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,179 shares of the company's stock after acquiring an additional...
    11/12 03:40 EST - defenseworld.net
    ABC Arbitrage SA Invests $2.24 Million in Zoetis Inc. $ZTS
    ABC Arbitrage SA acquired a new stake in Zoetis Inc. (NYSE: ZTS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 14,387 shares of the company's stock, valued at approximately $2,244,000. A number of other institutional...
    11/11 04:35 EST - fool.com
    2 Dividend Stocks to Double Up on Right Now
    Bad press has weighed on UnitedHealth Group and Zoetis. UnitedHealth Group faces controversy and investigations, but will likely survive and remain a key cog in America's healthcare system.
    11/08 07:28 EST - seekingalpha.com
    What Moved Markets This Week
    Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
    11/07 12:01 EST - seekingalpha.com
    Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
    Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side effects, overshadows growth in other segments and forces lowered revenue guidance. ZTS trades at a...
    11/06 09:36 EST - seekingalpha.com
    Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
    Zoetis Inc. is trading at historically low valuations despite continued EPS and margin growth, following a sharp post-earnings selloff. ZTS's Q3 results showed resilient profitability, but weaker guidance and slowing revenue growth triggered a market rerating from high to low growth. The company...
    11/05 18:00 EST - gurufocus.com
    Diamond Hill Capital's Strategic Moves: A Closer Look at Zoetis Inc.
    Exploring Diamond Hill Capital (Trades, Portfolio)'s Latest 13F Filing for Q3 2025 Diamond Hill Capital (Trades, Portfolio) recently submitted its 13F filing f
    11/04 16:16 EST - seekingalpha.com
    Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
    Zoetis Inc. ( ZTS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Steven Frank - Vice President of Investor Relations Kristin Peck - CEO & Director Wetteny Joseph - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division...
    11/04 13:15 EST - benzinga.com
    Zoetis Stock Outlook Clouded By Rising Competitive Pressures
    Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70.
    11/04 12:46 EST - zacks.com
    ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
    Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
    11/04 12:41 EST - seekingalpha.com
    Zoetis: No Longer A Growth Stock
    Zoetis shares have underperformed, falling over 25% in the past year, with recent guidance disappointing investors. Organic growth is slowing, especially in the United States, as core products reach market saturation and macro headwinds weigh on pet care spending. ZTS's valuation has compressed,...
    11/04 10:30 EST - zacks.com
    Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
    The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
    11/04 09:11 EST - zacks.com
    Zoetis (ZTS) Surpasses Q3 Earnings Estimates
    Zoetis (ZTS) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.58 per share a year ago.
    11/04 08:59 EST - barrons.com
    This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.
    Zoetis slashes its full-year outlook.

    Market News ×
    Loading news…